GBS - GBS STOCK NEWS

On October 4, 2022, GBS Inc. (Nasdaq: GBS) announced the acquisition of Intelligent Fingerprinting Limited (IFP), enhancing its leadership in non-invasive diagnostic testing. This strategic move expands GBS's portfolio to include IFP's proprietary 10-minute drug screening system, which analyzes fingerprint sweat to detect various substances. The acquisition provides GBS with access to over 200 IFP customers and a manufacturing facility in the UK. GBS plans to initiate regulatory approvals in Australia, aiming for a direct sales campaign in 2023.

On August 31, 2022, GBS Inc. (GBS) announced an exclusive agreement to acquire Intelligent Fingerprinting Ltd. (IFP), enhancing their drug screening technology portfolio. The company reported a preliminary net loss of $8.4 million for the fiscal year ending June 30, 2022, compared to a loss of $7.3 million the previous year. GBS has made significant progress with their saliva Glucose Biosensor, entering the final design phase, and plans to conduct two parallel clinical studies. GBS's cash and equivalents stood at approximately $8.2 million as of June 30, 2022, sufficient to cover expenses into H2 2023.

GBS Inc. is set to announce its financial results for Q4 and full year ended June 30, 2022, on August 31, 2022, after the NASDAQ market closes. The announcement will be followed by a conference call and webcast at 4:30 p.m. ET. GBS focuses on developing non-invasive, real-time diagnostic testing and has launched its Biosensor Platform for diabetes monitoring. Investors can access the live webcast and replay via the company's website.

GBS Inc. (Nasdaq: GBS) has completed a clinical study analyzing glucose levels in oral fluids and blood samples at Sutter Health’s Mills-Peninsula Medical Center. The study involved 40 adult subjects with type 2 diabetes, collecting nearly 1400 samples. The company aims to correlate glucose levels from various sample types using validated measurement methods developed with Johns Hopkins University. The results will support future regulatory submissions and guide further clinical studies anticipated in Q4 2022.

GBS Inc. (Nasdaq: GBS) has partnered with the University of Newcastle to establish a site for its innovative biosensor technology. The collaboration aims to enhance the production of saliva glucose biosensor test strips, which will assist diabetes patients. The initial phase of operations is set to begin with recently delivered equipment, while construction of a new state-of-the-art manufacturing facility is expected to start by the end of 2022. This partnership is crucial for advancing GBS's technology and expanding its market presence globally.

GBS Inc. (Nasdaq: GBS) has announced the adjournment of its 2022 Annual Meeting of Stockholders from June 16, 2022, to July 13, 2022, at 4:00 p.m. Eastern Time due to insufficient quorum. Stockholders are encouraged to vote prior to the meeting using the existing proxy materials, as the record date remains April 27, 2022. No changes have been made to the proposals for voting. Voting results will be announced after the adjourned meeting. Forward-looking statements reflect potential risks regarding the company's diagnostic tests and partnerships.

GBS Inc. has signed an exclusivity agreement to acquire Intelligent Fingerprinting Limited, focusing on enhancing its diagnostic testing capabilities. This acquisition aims to combine GBS's saliva-based glucose biosensor technology with Intelligent Fingerprinting's rapid drug screening system. The deal is expected to expand GBS's product offerings and accelerate revenue growth by serving a broader patient demographic. GBS has provided a $500,000 unsecured loan to Intelligent Fingerprinting as part of this agreement, with a decision on the acquisition expected by December 31, 2022.

GBS Inc. (Nasdaq: GBS), a life sciences company focused on non-invasive diagnostic testing, announced participation in the H.C. Wainwright Global Investment Conference scheduled for May 23–26, 2022. Dr. Steven Boyages, interim CEO, along with the management team, will engage in virtual one-on-one meetings with investors on May 24 at 7:00 AM ET. The conference aims to showcase GBS's innovative Biosensor Platform, which is essential for monitoring diabetes. Interested participants can register via the HCW events website for further engagement.

GBS Inc. (Nasdaq: GBS) announced its 2022 Annual Meeting of Shareholders, set for June 16, 2022, at 4:00 p.m. ET. The meeting will be virtual-only, allowing shareholders to vote electronically. Shareholders must have their control number to participate. Proxies can be submitted until 11:59 p.m. ET on June 15, 2022. The company emphasizes the importance of voting, urging those with control numbers to submit their votes in advance. Additional information is available on the company’s website.